Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2022-06-06 Environmental & Social …
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Data Presentations at ADA 82nd Scientific Sessions
Environmental & Social Information Classification · 99% confidence The document is identified by the RNS Number header and the date (06 June 2022), indicating it is a regulatory news service announcement. The content details the company's participation in the American Diabetes Association (ADA) Scientific Sessions, presenting data on their KidneyIntelX product. This is a general corporate update regarding scientific presentations and research findings, not a formal financial report (like 10-K or IR), a specific management change (MANG), or a dividend announcement (DIV). Since it is a general announcement distributed via RNS that doesn't fit into the more specific categories like ER, CT, or IP, the most appropriate classification is the general Regulatory Filings category, RNS, as it is explicitly distributed through the RNS system and serves as a broad update.
2022-06-06 English
KidneyIntelX data shows ability to assess risk
Environmental & Social Information Classification · 99% confidence The document is identified by the 'RNS Number' header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange. The content is a press release dated June 6, 2022, announcing positive clinical data for the KidneyIntelX test, presented at the American Diabetes Association Scientific Sessions and published in Kidney360. This type of announcement, which disseminates material, non-financial news to the market via an official channel (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, ER, or IR), nor is it a management change (MANG) or dividend notice (DIV). It is a general regulatory announcement.
2022-06-06 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and contains information about the 'Total voting rights' of Renalytix PLC as of April 29, 2022. It explicitly states the total number of shares and voting rights (74,760,432) and mentions this figure is used for notifications under the FCA's Disclosure and Transparency Rules. This type of announcement, which communicates a specific, required regulatory update (total share capital/voting rights), is a general regulatory announcement. Since it doesn't fit precisely into categories like Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue (SHA), and it is a standard regulatory disclosure provided via RNS, the most appropriate general category is Regulatory Filings (RNS). The document length is short (3560 chars), but it is a primary disclosure, not an announcement *about* another report, so RPA is less suitable than RNS for this specific type of mandatory update.
2022-04-29 English
Grant of Share Options
Remuneration Information Classification · 99% confidence The document is an official announcement disseminated via RNS (Regulatory News Service), indicated by the RNS Number and the closing statement referencing the London Stock Exchange and FCA. The content explicitly details the 'Grant of Share Options' to a Non-Executive Director (Tim Scannell) and includes structured tables typical of insider transaction reporting (Section 1, 2, 3, 4). This type of filing, reporting personal share transactions by company directors, directly corresponds to the 'Director's Dealing' category (DIRS). Although it is distributed via RNS, the specific content is not general regulatory news but a specific insider transaction report.
2022-04-22 English
Successful completion of $30.0m financing package
Director's Dealing Classification · 98% confidence The document is an official announcement released via RNS (Regulatory News Service) on April 8, 2022. The primary subject is the 'Successful completion of $30.0 million financing package' involving an equity subscription and convertible bonds. Crucially, the document also details 'Director/PDMR Dealing' where directors and senior management subscribed for New Ordinary Shares, including specific transaction details for Christopher Mills, Ann Berman, Timothy Scannell, and Thomas McLain. This combination of financing activity and mandatory disclosure of insider transactions strongly points towards a filing related to capital structure changes and insider dealings. Since the document explicitly details director/PDMR subscriptions following a financing event, it covers elements of both Capital/Financing Update (CAP) and Director's Dealing (DIRS). However, the structure, the RNS header, and the detailed disclosure tables (especially the section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them') are characteristic of mandatory regulatory disclosures concerning insider transactions. Given the dual nature, we must prioritize the most specific and mandatory disclosure element present. The detailed breakdown of director purchases aligns perfectly with the definition of Director's Dealing (DIRS). While it announces a financing package (CAP), the extensive focus on the PDMR participation makes DIRS the most accurate primary classification for this specific regulatory filing format.
2022-04-08 English
Issue of shares
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is identified by the presence of an 'RNS Number' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the 'Issue of shares' under an Employee Share Purchase Plan and the subsequent application for admission to trading on AIM, concluding with the 'Total voting rights' update. This type of announcement, which is a formal regulatory disclosure disseminated via the RNS system, fits best under the general 'Regulatory Filings' category (RNS), as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Although it relates to share capital changes, the primary context is the regulatory dissemination via RNS.
2022-04-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.